Tenofovir Alafenamide Fumarate and Epstein-Barr virus activity in people with MS – The TAF-MS study

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503814-62-00

Enrollment

Registered

2023-11-20

Start date

2024-02-06

Completion date

2025-11-14

Last updated

2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis

Brief summary

Total number of SAEs from baseline to 24 weeks after start of study treatment

Detailed description

Change in IgG antibodies to EBNA1 and other EBV antigens from baseline to 2, 8 and 24 weeks after start of study treatment., Change in EBV viral load in saliva from baseline to 2, 8 and 24 weeks after start of study treatment., Key secondary endpoints Change in EBV shedding in saliva

Interventions

DRUGCapsule coated tablets

DRUGTysabri 300 mg concentrate for solution for infusion

DRUGVemlidy 25 mg film-coated tablets.

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Total number of SAEs from baseline to 24 weeks after start of study treatment	—

Secondary

Measure	Time frame
Change in IgG antibodies to EBNA1 and other EBV antigens from baseline to 2, 8 and 24 weeks after start of study treatment., Change in EBV viral load in saliva from baseline to 2, 8 and 24 weeks after start of study treatment., Key secondary endpoints Change in EBV shedding in saliva	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026